Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. - Wikidata - awgldk - TriplyDB

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

http://www.wikidata.org/entity/Q45007178

about

Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease Clinical immunologic approaches for the treatment of Alzheimer's disease Immunotherapy as treatment for Alzheimer’s disease 11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Plasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementia Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation Hsp90-Tau complex reveals molecular basis for specificity in chaperone action Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity Active and passive immunotherapy for neurodegenerative disorders Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease.The genetic landscape of Alzheimer disease: clinical implications and perspectives Diverse molecular targets for therapeutic strategies in Alzheimer's disease Testing the right target and right drug at the right stage Alzheimer's disease pathologic cascades: who comes first, what drives what Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease The role of tau in neurodegenerative diseases and its potential as a therapeutic target Tau-targeted treatment strategies in Alzheimer's disease ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease The ubiquitin-proteasome system in Alzheimer's disease Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2 A novel calcium-binding protein is associated with tau proteins in tauopathy Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease Tau suppression in a neurodegenerative mouse model improves memory function The role of microglia in brain maintenance: implications for Rett syndrome.Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4.Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.β-Amyloid impairs axonal BDNF retrograde trafficking.Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

P2860

Q21144713-869B88EC-B7D4-49A2-AB40-FBC9BD210D18 Q22241380-50082631-9A35-4928-B184-D65B270356D0 Q22241491-33A2E4CA-D6F2-42B0-AF36-8C9CCD281ECB Q24194742-33FCB23E-87A9-4996-8CC7-1FE7B3B4E549 Q24201039-A8C1CBCD-1BBD-42AD-B03A-26168ADC2FE4 Q24235058-E0A7C030-1DB5-4F89-B642-79DA802B07B4 Q24305254-CB5C39E2-AC7F-43BA-B3F2-BB3A6098906A Q24338439-B21A34DC-52FA-485D-BDD4-F979C81EF845 Q24595310-2DBFE2FF-FA26-427D-8A9F-A1572B297432 Q24599108-CCC4D340-FF32-4900-AFA4-665AD755CEB7 Q24608911-7C816925-612B-465D-A5F8-8063226CF66E Q24633947-15A6BC4B-BD05-486D-BC37-5036514111CB Q24634209-3AF5FBB7-7C77-424F-B187-D1C0B59B13BE Q24657879-77FED763-CC17-4C22-94FA-A284755D0CE8 Q24676179-019ACD3C-690A-443B-9F8B-6478921EC37D Q24681736-FC17607B-FE9F-408A-A90E-24628BD827E8 Q24791704-015FEEB8-D080-49D5-87C3-33C286356E43 Q25256570-C3FB7B01-7DA2-4EA1-B5CF-6953722374D7 Q26796582-38902D1B-EA50-4283-8580-F0B0300CC59F Q26827193-9D4D35FD-53B0-4081-B536-73556EF8D9E0 Q26864854-139643E0-D3C8-43D8-8862-A9F0C8E5946A Q26995896-ED0E4C2C-6B63-47A2-A899-55848899ED13 Q27003841-DB5F4E6D-810C-42F9-A73D-2529B2B080F0 Q27005032-CCB08F01-3BA3-432D-9727-3139B6AFA570 Q27023429-AFF57B21-ACAD-4EA7-9824-95E9C2A4FEAB Q28081654-C1821A76-1103-469A-BFDE-78384C0E57BC Q28268311-290D6CBD-DA57-446B-9ED9-794AEB72A873 Q28482267-541DDBAA-D216-4831-A931-1FB1CFF29E1E Q28584873-8C929BCA-D813-460B-BA3F-0B127DBC0101 Q28740634-718C76EA-F9B9-4C06-914A-B0D58BF2A5CD Q29615831-BBFE7F60-9762-45A3-8690-C5C5588BACC5 Q30414657-DF5299A4-9DB9-454E-A952-4625D8E449AA Q30482492-C5B5B711-27BE-4A7D-ADB3-DFB36BFA357D Q30491040-78B184F1-71B3-4178-BD92-BF3688139AC1 Q30495675-9B4491F5-2C4A-444E-A98F-D68EA944881C Q30498160-A2F3B3B4-EC54-4C03-A1DB-D56BF25452B0 Q30499456-296F8795-06E1-479C-B792-23464EFF2F2A Q30539812-0BC62C65-91C7-4BDF-BAEE-15773B9145D6 Q30833707-2468538D-619A-46FB-A800-06EFF7F48EEB Q33289262-64CA3038-8E74-4726-9DD7-A1A9D7A7EB56

P2860

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

http://www.wikidata.org/entity/Q45007178

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@en

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@nl

type

label

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@en

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@nl

prefLabel

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@en

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@nl

P1433

Q45007178-272FA746-6EC0-499A-9DCF-C04651DDD066

P1476

Q45007178-24C2DB6E-3BD0-4365-ABD0-7F27E1A93C2B

P2093

Q45007178-34252986-2C59-4344-A37F-8F27E3BF447A

Q45007178-4AAC0F91-89E9-42BA-B16C-48B1A3CDB8C8

Q45007178-6AC72844-499C-4FB5-88A7-43EB80AFB9DE

Q45007178-828383FE-647A-42B3-BA96-EF3F4F648B7A

Q45007178-B249B3D3-F07C-4BA0-9CCA-169B87555048

P304

Q45007178-3C3677F1-FCA4-4E48-9CE1-29C41BAA6465

P31

Q45007178-33923EB3-5011-4AB4-8C5C-98C8E9F04698

P356

Q45007178-DFE8AE20-9168-4868-A630-5716DFF10FF9

P407

Q45007178-9A8F2A72-3DB6-42E6-8AAC-2E17BF61A0F9

P433

Q45007178-AC1491F8-55FC-4ABC-89E6-654097A6BF5E

P478

Q45007178-1ADE6CE6-A1E2-4AB2-B35F-B7626D45AB3C

P577

Q45007178-BE6757C7-6AC1-4457-935D-6A4276769638

P5875

Q45007178-5D16EE3C-C1F4-4593-B867-669FA2E6E48B

P698

Q45007178-A00F3EC5-EA80-4840-AE25-B540294D0F13

P921

Q45007178-CF6E153D-603D-42E0-A788-630F8FC5B98A

P356

J.NEURON.2004.07.003

P1433

P1476

Abeta immunotherapy leads to c ...... aggregates via the proteasome.

@en

P2093

David H Cribbs

http://www.w3.org/2001/XMLSchema#string

Frank M LaFerla

http://www.w3.org/2001/XMLSchema#string

J Patrick Kesslak

http://www.w3.org/2001/XMLSchema#string

Lauren Billings

http://www.w3.org/2001/XMLSchema#string

Salvatore Oddo

http://www.w3.org/2001/XMLSchema#string

P304

321-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEURON.2004.07.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253126561

http://www.w3.org/2001/XMLSchema#string

P698

15294141

http://www.w3.org/2001/XMLSchema#string

P921